Trials / Active Not Recruiting
Active Not RecruitingNCT03843359
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3745417 | GSK3745417 will be administered. |
| DRUG | Dostarlimab | Dostarlimab will be administered. |
Timeline
- Start date
- 2019-03-12
- Primary completion
- 2024-04-04
- Completion
- 2026-03-31
- First posted
- 2019-02-18
- Last updated
- 2026-01-08
- Results posted
- 2026-01-08
Locations
13 sites across 8 countries: United States, Australia, Canada, France, Japan, Netherlands, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03843359. Inclusion in this directory is not an endorsement.